Showing 101 results
- Key Release /Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
- Key Release /Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):…
- Media Release /Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1…
- Media Release /COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma1 Adjuvant…
- Media Release /Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1Benefit seen…
- Media Release /New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline…
- Media Release /Patient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
- Media Release /Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
- Media Release /New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- › Next page